The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The newly certified kits are designed for early detection and large-scale screening programs
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Subscribe To Our Newsletter & Stay Updated